SCHEMBL4630734

SCHEMBL4630734

O=C(O)c1ccccc1C(O)c1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
ALOX15 P16050 1/20 0.52
MAPT P10636 2/20 0.48
HDAC8 Q9BY41 1/20 0.48
SRC P12931 1/20 0.46
KDM4E B2RXH2 2/20 0.46
TAAR1 Q96RJ0 1/20 0.46
MEN1 O00255 1/20 0.46
CYP2C9 P11712 1/20 0.46
LMNA P02545 3/20 0.45
MAPK1 P28482 1/20 0.45
CA12 O43570 1/20 0.45
CA1 P00915 1/20 0.45
CA2 P00918 1/20 0.45
HMGB1 P09429 1/20 0.45
HPGD P15428 1/20 0.45
CA4 P22748 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21652595 0.89 SRD5A2 (0.56) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL12979661 0.88 SRC (0.46) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL30251446 0.87 ALDH1A1 (0.47) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL28199599 0.87 ALDH1A1 (0.51) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL4192923 0.84 BCAT2 (0.46) ALDH1A1KMT2AGAATDP1MAPT
SCHEMBL11603922 0.83 ALDH1A1 (0.55) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL28193779 0.83 ALDH1A1 (0.44) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL9580764 0.82 LMNA (0.55) ALDH1A1KMT2AGAATDP1ALOX15
SCHEMBL27543079 0.82 AKR1C3 (0.52) ALDH1A1KMT2AGAATDP1MAPT
SCHEMBL11602789 0.82 ALDH1A1 (0.62) ALDH1A1KMT2AGAATDP1ALOX15

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120154564-A Preparation method of stable veterinary oral paste composition 北京欧博方医药科技有限公司 2025-06-17 CN claimed
CN-118632933-A Screening method for substance inhibiting odor of 4-methylacetophenone and method for inhibiting odor of 4-methylacetophenone 味之素株式会社 2024-09-10 CN disclosed
CN-118591301-A Method for inhibiting odor of p-cresol 味之素株式会社 2024-09-03 CN disclosed
CN-117396490-A Bicyclic heterocyclic compounds for the prevention and treatment of viral infections BM医药咨询有限公司 2024-01-12 CN disclosed
CN-116332809-A Process for producing alkylamine derivative and intermediate for production thereof 味之素株式会社 2023-06-27 CN disclosed
CN-115536556-A Process for producing alkylamine derivative and intermediate for producing the same 味之素株式会社 2022-12-30 CN disclosed
CN-108699580-B Heparan sulphate with a high 3-O-sulphation ratio in the glucosamine residue 味之素株式会社 2022-09-23 CN disclosed
CN-114657079-A Yeast with high content of Abu, gamma-Glu-Abu and/or gamma-Glu-Abu-Gly 味之素株式会社 2022-06-24 CN disclosed
CN-113473977-A Cannabidiol and/or derivatives thereof for use in the treatment of mitochondrial diseases 巴塞罗那自治大学 2021-10-01 CN disclosed
EP-3134443-B1 LED PHOTOINITIATORS SUN CHEMICAL CORP (US) 2019-10-30 EP disclosed
EP-3416647-A2 N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS Merck Sharp & Dohme Corp. (US) 2018-12-26 EP disclosed
WO-2017142825-A2 N3-SUBSTITUTED IMINOPYRIMIDINONES AS ANTIMALARIAL AGENTS MERCK SHARP & DOHME CORP. (US) 2017-08-24 WO disclosed
CN-102781354-B To high speed Rotational atherectomy system, the apparatus and method of biological duct topical application therapeutic agent CARDIOVASCULAR SYSTEMS, INC. (US) 2016-03-30 CN disclosed
CN-102762168-B Therapeutic agent delivery system for topical application of therapeutic substances to biological conduits CARDIOVASCULAR SYSTEMS, INC. (US) 2015-08-26 CN disclosed
CN-102917655-B Therapeutic agent delivery system, device and method for localized application of therapeutic substances to a biological conduit CARDIVASCULAR SYSTEMS 2015-07-08 CN disclosed
US-20100298296-A1 Oligomer-Tricyclic Conjugates NEKTAR THERAPEUTICS (US) 2010-11-25 US disclosed
WO-2009073154-A1 OLIGOMER-TRICYCLIC CONJUGATES NEKTAR THERAPEUTICS AL, CORPORATION (US) 2009-06-11 WO disclosed
EP-1869269-A4 ANTI-CASTER SURFACE LAMINATE LG CHEMICAL LTD (KR) 2008-05-21 EP disclosed
EP-1869269-A1 ANTI-CASTER SURFACE LAMINATE LG Chemical Co. Ltd (KR) 2007-12-26 EP disclosed
WO-2006109914-A1 ANTI-CASTER SURFACE LAMINATE LG CHEM, LTD. (KR) 2006-10-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100298296-A1 Oligomer-Tricyclic Conjugates ABCG2, SLCO1B3, SLC43A1 ALDH1A1 2609/4885KMT2A 3267/4885GAA 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.